Myriad Genetics

Myriad Genetics

Myriad Genetics was founded in 1991 and is headquartered in Salt Lake City, Utah. The company operates as a publicly traded diagnostics firm, not a family office, with a focus on genetic and tumor genomic testing. The company groups its tests into five health areas: hereditary cancer risk, reproductive health, oncology, urology, and mental health. In oncology, it offers germline and tumor genomic testing to identify actionable variants and biomarkers associated with FDA-approved therapies. Its urology test assesses prostate cancer aggressiveness, and its mental health offering uses pharmacogenomics to predict patient response to antidepressants. Myriad covers the US healthcare market, with its data repository spanning all ancestries. Myriad employs approximately 2,200 people per public filings. The company has not disclosed a specific number of professionals, but operates as a commercial diagnostics business with revenue from test sales. It maintains a large repository of comparative genetic data covering all ancestries, which it uses to develop inclusive tests. The company has not reported any recent operational events material to its corporate structure in the last 24 months. What distinguishes Myriad Genetics is its long-established position in hereditary cancer testing and its shift toward comprehensive genomic profiling across multiple specialties. The company develops its own tests internally and partners with healthcare providers rather than operating as a passive capital vehicle.